Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Status:
Recruiting
Trial end date:
2023-09-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetic, safety, immunogenicity and
efficacy of CMAB819 and Nivolumab in subjects with recurrent or metastatic head and neck
squamous cell carcinoma., after failure of prior platinum-based chemotherapy.